IGR_CAP1_DOCETAXEL_GE_STUDY_AC

ABSTRACT: 'Prostate cancer is the second cancer diagnosed among men worldwide. Beside approval of new therapies in the last five years, chemotherapeutic agents, docetaxel and cabazitaxel taxanes remain key treatments for metastatic castration resistant prostate cancers. However, primary and acquired resistance to taxanes still emerged in about half of patients. There is therefore an urgent need to discover and understand the taxane resistance mechanisms in order to identify new therapeutic targets. Indeed, targeted therapies that exploit the signaling pathways involved in prostate cancer are required to overcome chemoresistance and improve treatment outcomes. Molecular chaperones play a key role in the regulation of cellular homeostasis and the development of treatment resistance, and are promising

ORGANISM(S): Homo sapiens

SUBMITTER: Anne Chauchereau 

PROVIDER: E-MTAB-4869 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress